Fox Run Management’s Pyxis Oncology PYXS Stock Holding History

Fox Run Management’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,566	Closed	-$26K	–	1178
2025 Q4	$26K	Buy	+22,566	New	+$79.6K	﹤0.01%	867

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's PYXS Position: Q1 2026 in Review

Fox Run Management sold out of Pyxis Oncology (PYXS) in Q1 2026, closing a stake of 22,566 shares — an estimated $26K sold.

Fox Run Management first reported a position in PYXS in Q4 2025 and held it in 1 quarter. The position peaked at $26K in Q4 2025. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

Fox Run Management reported no remaining Pyxis Oncology position as of Q1 2026 after selling out during the quarter.
Fox Run Management sold 22,566 Pyxis Oncology shares in Q1 2026, an estimated $26K.
Fox Run Management first reported a position in Pyxis Oncology in Q4 2025 and held it in 1 quarter.
Fox Run Management's Pyxis Oncology position peaked at $26K in Q4 2025.
78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Fox Run Management's 13F filing for Q1 2026, filed 12 May 2026.